Business Wire

Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange

Share

Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange (“TSE”) in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda’s website at: https://www.takeda.com/who-we-are/corporate-governance/.

This report is prepared based on the revised Corporate Governance Code as in effect as of June 11, 2021. It describes the latest corporate governance features of our Company, including the new structure of the Board of Directors after the 146th General Shareholder’s Meeting held on June 29, 2022.

Key elements of Takeda’s Corporate Governance Report:

  • Takeda aims for increased transparency and objectivity of the Board of Directors by maintaining the high composition ratio of Independent External Directors (4 Internal Directors and 11 Independent External Directors) and having an independent external director serve as the Chair of the Board meeting.
  • The Board of Directors is composed of diverse members with various background, experiences and knowledge (BOD Skill Matrix), to help enable strategic discussions and effective supervision of the Company.
  • The Audit and Supervisory Committee, and the Nomination/Compensation Committees as advisory committees for the Board of Directors are composed entirely of Independent External Directors, including each head/chairperson, in order to ensure the independence of each committee.
  • Internal directors receive a certain level of delegation of authority from the Board of Directors, and the Takeda Executive Team, which is diverse in terms of background, nationality, gender, and age, ensures agile and efficient decision-making based on strategic discussions at the management committee meetings.

Takeda’s latest Corporate Governance Report can be found at the information disclosure site operated by the Japan Exchange Group which consists of the TSE and other exchanges in Japan at:
https://www2.jpx.co.jp/tseHpFront/CGK020010Action.do?Show=Show

Takeda also furnished the English version of the Corporate Governance Report with the U.S. Securities and Exchange Commission (the “SEC”), available at www.sec.gov.

Additionally, Takeda’s corporate governance policy as well as overall Environmental, Social and Governance information is explained in detail in its 2022 Annual Integrated Report for the fiscal year ended March 31, 2022. This report can be accessed on Takeda’s website at: https://www.takeda.com/corporate-responsibility/reporting-on-sustainability/annual-integrated-report/

*TSE’s Securities Listing Regulations [Rule 419].

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:

Japanese Media
Jun Saito
jun.saito@takeda.com
+81 (0) 3-3278-2325

U.S. and International Media
Megan Ostrower
megan.ostrower@takeda.com
+1 772-559-4924

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altium, IPC Education Foundation, and Arduino Announce Student Electronics Design Competition18.8.2022 07:00:00 CEST | Press release

Altium LLC, the leading printed circuit board (PCB) design software company, is partnering with the IPC Education Foundation (IPCEF) and Arduino to launch the second annual student electronics design challenge. This competition aims to engage, educate, and enhance PCB design capabilities while developing STEM solutions to environmental challenges. The electronics design challenge is an excellent opportunity for students to showcase their talents and gain real-world experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005660/en/ Altium LLC, the IPC Education Foundation, and Arduino are partnering to launch the second annual student electronics design challenge to engage, educate, and enhance students’ proficiencies in PCB design capabilities with a focus on solving some of the world’s most pressing environmental challenges. (Photo: Altium LLC) The Innovation for Environmental Change 2022 International Student Desi

Tavneos ® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)18.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), two main forms of AAV. The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005538/en/ “ANCA-associated vasculitis is a rare, systemic disease which can be rapidly fatal if not appropriately & promptly treated. The variable nature of the disease and its course along with challenging side-effects of current treatment options can severely affect subsequent quality of life for patients,” said John Mills, Vice-Chair of Vasculitis UK. “We very much welcome NICE’

Pre-registration Opens for Hotly Anticipated Racing Game KartRider: Drift18.8.2022 06:01:00 CEST | Press release

Starting today, Nexon’s upcoming party game, KartRider: Drift, is opening pre-registration to racers in preparation for the game’s launch on PC (Steam and Nexon Launcher), Xbox One, PlayStation 4, and mobile (iOS and Android). Kart racer fans who sign up beforehand can receive a special character Model Student Diz when the game officially launches. Additionally, an upcoming cross-platform play test will be announced soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005798/en/ Nexon America KartRider: Drift (Graphic: Nexon) KartRider: Drift boasts multiple game modes and features, delivering exciting racing gameplay regardless of what platform you choose to play. 3 Thrilling Game Modes – Racers can test their grit in “Speed Mode,” a fast-paced mode that will test a racer's reaction skills and strategy using boosts. “Item Mode” offers a wide variety of usable items to attack opposing teams or defend their allies. Fina

Exscientia Business Update for Second Quarter and First Half 202217.8.2022 22:01:00 CEST | Press release

Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005681/en/ Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the company’s pipeline and corporate strategy. “In the first half of 2022, we delivered on major new and existing collaborations, advanced our pipeline programmes, and marked the 10-year anniversary of Exscientia’s founding. Over the past decade, we’ve pioneered an AI-driven approach to modernising drug discovery and development, and it was fitting that this quarter we also announced topline data from our EXS-21546 programme, one of the first AI-designed molecules to enter clinical trials,” said Andrew Hopkins, D.Phil., Exscientia's f

Watts Water Technologies Completes WAVE Water Stewardship Verification17.8.2022 17:00:00 CEST | Press release

Watts Water Technologies, Inc. — one of the world’s leading manufacturers and providers of plumbing, heating, and water quality products and solutions — has successfully completed verification for The Water Council’s WAVE: Water Stewardship Verified program, indicating the company has assessed water-related risk across the enterprise, identified the highest water-related impacts using credible water-related data and implemented best practice in improving water stewardship performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005123/en/ (Graphic: Business Wire) During the WAVE process, Watts prioritized eight of its sites with the highest water risk, identified the watersheds in which it operates, conducted a water balance to learn more about its water inputs and outputs, and engaged the community around its selected sites. As a result, Watts took a variety of actions at the local and global level to reduce water